Sanofi SA SAN
News
Sanofi ships U.S. influenza vaccines for the 2024/25 season
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Sanofi On Pace for Largest Percent Decrease Since October 2023 — Data Talk
Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Sanofi on Pace for Largest Percent Decrease Since October 2023 — Data Talk
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD